Velaglucerase alfa explained
| Verifiedfields: | changed |
| Watchedfields: | changed |
| Verifiedrevid: | 470629507 |
| Tradename: | Vpriv |
| Dailymedid: | Velaglucerase alfa |
| Routes Of Administration: | Intravenous |
| Atc Prefix: | A16 |
| Atc Suffix: | AB10 |
| Legal Au: | S4 |
| Legal Us: | Rx-only |
| Legal Eu: | Rx-only |
| Legal Status: | Rx-only |
| Bioavailability: | N/A |
| Elimination Half-Life: | Plasma 5–12 minutes (absorbed by macrophages)
|
| Cas Number: | 884604-91-5 |
| Drugbank: | DB06720 |
| Chemspiderid: | none |
| Unii: | 23HYE36B0I |
| Kegg: | D09029 |
| Chembl: | 1201865 |
| C: | 2532 |
| H: | 3850 |
| N: | 672 |
| O: | 711 |
| S: | 16 |
Velaglucerase alfa, sold under the brand name Vpriv, is a medication used for the treatment of Gaucher disease Type 1. It is a hydrolytic lysosomal glucocerebroside-specific enzyme, which is a recombinant form of glucocerebrosidase. It has an identical amino acid sequence to the naturally occurring enzyme.[1] It is manufactured by Shire plc.
The most common side effects include abdominal (belly) pain, headache, dizziness, bone pain, arthralgia (joint pain), back pain, infusion-related reactions, asthenia (weakness) or fatigue (tiredness), and pyrexia (fever) or increased body temperature.
Velaglucerase alfa was approved for medical use in the United States in February 2010,[2] [3] and in the European Union in August 2010.[4]
Medical uses
Velaglucerase alfa is indicated for long-term enzyme-replacement therapy (ERT) in people with type-1 Gaucher disease.[5]
Notes and References
- Burrow TA, Grabowski GA . Velaglucerase alfa in the treatment of Gaucher disease type 1 . Clinical Investigation . 1 . 2 . 285–293 . February 2011 . 21927713 . 3172711 . 10.4155/cli.10.21 .
- Web site: Medical News Today . Shire Announces FDA Approval Of Vpriv (velaglucerase Alfa For Injection) For The Treatment Of Type 1 Gaucher Disease . 27 February 2010 . 6 March 2010 . 13 June 2011 . https://web.archive.org/web/20110613222314/http://www.medicalnewstoday.com/releases/180630.php . dead .
- Web site: Drug Approval Package: Vpriv (Velaglucerase alfa) NDA #022575 . U.S. Food and Drug Administration (FDA) . 24 February 2010 . 17 February 2023 . 3 April 2021 . https://web.archive.org/web/20210403003943/https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022575s000TOC.cfm . live .
- Web site: Vpriv EPAR . European Medicines Agency (EMA) . 17 September 2018 . 13 August 2020 . 29 October 2020 . https://web.archive.org/web/20201029205412/https://www.ema.europa.eu/en/medicines/human/EPAR/vpriv . live . Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- Web site: Vpriv- velaglucerase alfa injection, powder, lyophilized, for solution . DailyMed . 18 June 2020 . 13 August 2020 . 24 March 2021 . https://web.archive.org/web/20210324151719/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ca02f7a4-ae4f-43c1-a06a-259fe4fcf9cf . live .
